Abstract:Background: As one of the most common causes of stroke, symptomatic intracranial artery stenosis (sICAS) is a great threat to public health, and its financial burden is substantial, with annual direct high medical costs particularly in China. Currently, the long-term use of conventional dual antiplatelet therapy (DAPT) as the primary modality of treatment for sICAS decreases the risk of stroke recurrence but increases the risk of bleeding. We aimed to evaluate the efficacy and safety of low dose aspirin plus clopidogrel for the treatment of sICAS in the elderly population. Methods: This randomized, controlled study included 181 older patients with transient ischemic attack (TIA) or ischemic stroke (IS) attributed to sICAS, who were recruited between April 2015 and November 2020. The 90 patients assigned to the low dose therapy group included aspirin, 75 mg, plus clopidogrel, 50 mg, daily for 90 and 91 patients assigned to the conventional group included aspirin, 100 mg, plus clopidogrel, 75 mg, daily for 90 days (aspirin or clopidogrel alone daily thereafter) were included in this intention-to-treat analysis. Efficacy and safety analyses were done in this trial. Results: One hundred eighty-one eligible elderly patients with sICAS were enrolled in this trial. The median age was 70 years ranged 60-83 years. Seventy-five participants were with TIA and 106 with IS. The median time of follow-up was 30 months ranged 1-36 months. Ninety patients were assigned randomly to the low dose group and 91 patients to the conventional group. The rate of primary, secondary and composite efficacy were not significantly different between the low dose and conventional group (P > 0.05). The rate of composite safety outcome was 7.8% (7/90) in the low dose group, which was lower than 17.6% (16/91) in the conventional group (χ2 = 3.921, P = 0.048). At the time of last follow-up, 17 (9.4%) of 181 patients developed GI injuries, which occurred in four (4.4%) of 90 patients in the low dose group and in 13 (14.3%) of 91 patients in the conventional group (χ2 = 4.058, P = 0.044). The primary efficacy outcome occurred in six (18.2%) of 33 patients with severe sICAS and in 22 (38.6%) of 57 patients with moderate sICAS (χ2 = 4.064, P = 0.044) in the low dose group. Conclusion: In this study, the safety of low dose aspirin combined with clopidogrel proved to be equally efficient and significantly safer than those of conventional dose within 24 months in elderly patients with sICAS. However, the small size of this study limits the validity of the results. Further larger longitudinal and randomized controlled trials are necessary to evaluate the role of low dose DAPT in the patients with sICAS.

Optimal Low Dosage of Acetylsalicylic Acid (ASA) for the Prevention and Treatment of Ischemic Cerebrovascular Disease in Geriatric Patients.

Aspirin Resistance in the Elder Cardio-Cerebral-Vascular Diseases Patients

Dose-response of Aspirin on Platelet Function in Very Elderly Patients

Safety of Early Antiplatelet Therapy for Non-Cardioembolic Mild Stroke Patients with Thrombocytopenia.

Anti-aggregation Effect and Short-term Safety Evaluation of Low-dose Aspirin Therapy in the Elderly Chinese Population: a Multicenter Randomized Controlled Clinical Trial

Effects of Compound Red-rooted Salvia and Aspirin on Platelet Aggregation and PKB Activity in the Elderly Patients with ACS

Efficacy and safety of low dose aspirin plus clopidogrel in the treatment of elderly patients with symptomatic intracranial artery stenosis

Outcomes Associated with 50 Mg/d and 100 Mg/d Aspirin for the Prevention and Management of Cardiovascular Disease in Chinese Elderly: Single-Center Interim Analysis of a Multicenter, Prospective, Observational Study

Adverse effects of low-dose aspirin in a healthy elderly population

The Effect of Different Dosage of Aspirin on Inflammatory Biomarkers and Prognosis in Acute Coronary Syndrome

Evaluating the effect of different doses of aspirin on the platelet inhibition rate by thromboelastography

Aspirin Response and Related Factors in Aged Patients

Association Between Renal Function and Platelet Reactivity During Aspirin Therapy in Elderly Patients with Atherosclerotic Cardiovascular Disease

The Investigation of Pharmacokinetics and Pharmacodynamics on Different Doses and Administratire Ways of Aspirin

Effect of Low-Dose Aspirin on Serum Uric Acid Levels in Chinese Individuals over 60: Subanalysis of a Multicentre Randomized Clinical Trial.

Clinical observation for aspirin inhibits platelet aggregation in patients with coronary heart disease

Upper Gastrointestinal Bleeding Induced by Low-Dose Aspirin in Prevention of Coronary Disease

Homocysteine is a novel risk factor for suboptimal response of blood platelets to acetylsalicylic acid in coronary artery disease: a randomized multicenter study

Effect of Combination Therapy with Pravastatin and Aspirin to Blood Lipid and Inflammatory Marker

Comparison of Safety and Efficacy Between Clopidogrel and Ticagrelor in Elderly Patients With Acute Coronary Syndrome: A Systematic Review and Meta-Analysis

Targeting memory loss with aspirin, a molecular mechanism perspective for future therapeutic approaches